Factor V Leiden: Quick Facts
Dr. Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital & Research Center, shared a post on, recently shared on X:
“Factor V Leiden – Hematology Thread
Most common inherited thrombophilia
Everything you need: pathophysiology, risks, management, MCQ, OSCE
- What is Factor V Leiden?
Mutation in F5 gene (Arg506Gln) → resistance to activated protein C (APC)
Results in prolonged clotting activity → high risk of venous thromboembolism (VTE)
- Prevalence
3–8% in Caucasians
Heterozygous: ~7x higher VTE risk
Homozygous: ~20–80x higher VTE risk
Rare in Asians, Africans
- When to Suspect
Unprovoked VTE <50 yrs
Recurrent VTE
VTE in unusual sites (e.g., cerebral, mesenteric veins)
Strong family hx of clots
Neonatal purpura fulminans (if compound with protein C deficiency)
OCP or pregnancy-related clots
- Testing
Start with APC resistance assay
Confirm with DNA test for F5 mutation
Only test if results will change management (per ASH)
- Management – Acute VTE
Anticoagulate as per standard (DOACs, warfarin, LMWH)
Duration: depends on risk of recurrence
No need to treat asymptomatic heterozygotes
- Pregnancy
Heterozygous, no VTE history: no routine anticoagulation
Heterozygous + VTE history: LMWH throughout pregnancy + 6 weeks postpartum
Homozygous or compound mutation: prophylaxis recommended
- Avoid
Estrogen-based OCPs
Smoking
Prolonged immobility without prophylaxis
- Exam Pearls
Most common inherited thrombophilia
higher DVT > PE
DOACs preferred unless contraindicated
Routine screening not recommended
Counsel before OCPs, pregnancy, surgery
- MCQ
30 year old female with 1st unprovoked DVT, heterozygous FVL, no other RFs. Completed 6 mo anticoagulation. What next?
Stop anticoagulation; counsel on OCP risks and recurrence prevention
- OSCE Scenario 1
Young woman with VTE on OCP
Take history
Order FVL test if family history
Counsel on stopping estrogen, using progestin-only methods
- OSCE Scenario 2
Pregnant FVL heterozygote, no prior VTE
Explain that prophylaxis is not needed unless additional risks
Plan close monitoring, early postpartum prophylaxis if needed
- OSCE Scenario 3
Homozygous FVL patient needing surgery
Plan perioperative LMWH
Counsel on risk, early ambulation, compression devices
- Landmark References (Aug 2025)
1.NCCN 2025 – Thrombophilia & VTE risk stratification
2.ASH 2023 – Management guidelines on inherited thrombophilia
3.GeneReviews – Factor V Leiden update July 2024
4.BMJ 2022 – Risk of VTE recurrence in FVL
5.Front Cardiovasc Med 2022 – Meta-analysis on FVL and VTE recurrence.”
Stay updated on the latest with Hemostasis Today.
-
Oct 10, 2025, 16:15Roshan PK: Breaking Down Pulmonary Embolism Treatment By Risk Level
-
Oct 10, 2025, 12:21Chris Barber Echoes PPTA’s Call to Recognize the Lifesaving Work of Plasma Collection Teams Worldwide
-
Oct 10, 2025, 12:14William Aird: Thalassemia Trait is a Quiet Experiment of Nature
-
Oct 9, 2025, 19:53Wilfried Dinh: Top 10 Thrombosis And Antithrombotic Therapy Papers Of 2024
-
Oct 9, 2025, 13:12Abdul Mannan - Ferritin After IV Iron: Timing Matters
-
Oct 10, 2025, 12:23Bhavya Venkatesh: Talin Autoinhibition Is Required For Normal Hemostasis
-
Oct 10, 2025, 12:19Divyaswathi Citla Sridhar: Excited to Share Our Multicenter Study on Platelet Function Disorders, Now Published
-
Oct 10, 2025, 12:18Roberta Gualtierotti: We Evaluated Different Variables of the Cleaved HK Method in C1-Inhibitor Defects
-
Oct 10, 2025, 12:17Jamie Madrigal And The Team - Mathematical Analysis Of Emicizumab: Affinity-Driven Complex Formation And Lipid-Surface Reactions
-
Oct 10, 2025, 03:09Giuseppe Lippi: We Show Here That Red Light Therapy Offers Promise in High-Risk Patients
-
Oct 10, 2025, 12:25Robert Lewis: T Cells Are Wonderful - But They Can't Do Everything
-
Oct 9, 2025, 13:03Peter Graves: When the Bleeding Does Not Stop
-
Oct 8, 2025, 12:44Bobur Kholikov: Thrombosis Diagnostics with YHLO
-
Oct 7, 2025, 13:06Bobur Kholikov on iFlash Thrombosis Panel – D-Dimer
-
Oct 7, 2025, 03:502025 Nobel Prize: A Milestone for Autoimmunity Research - Awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi
-
Oct 10, 2025, 03:10Marilena Vrana: Plasma-Derived Medicines Are a Clear Example of Why A One-Size-Fits-All Approach Won’t Work
-
Oct 10, 2025, 03:07Nancy Di Salvo: It's IPAW 2025, How Could I Not Take a Moment to Thank Every Single Plasma Donor Out There?
-
Oct 10, 2025, 03:06Anita Brikman: Increasing Awareness of The Ongoing Need for Plasma Donors Is Vital to Ensuring Patient Access and Continuity of Care
-
Oct 10, 2025, 03:04Stephen Cornelissen: A New Plasma Drop Has Been Added to Lifeblood’s Blood Supply Tracker
-
Oct 10, 2025, 02:12Bethany Samuelson Bannow Welcomed to Department of Hematology and Medical Oncology at the Cancer Institute Cleveland Clinic